These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22419713)

  • 1. Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study.
    Ramírez C; Cheng S; Vargas G; Asa SL; Ezzat S; González B; Cabrera L; Guinto G; Mercado M
    J Clin Endocrinol Metab; 2012 May; 97(5):1745-51. PubMed ID: 22419713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
    Vieria Neto L; Wildemberg LE; Colli LM; Kasuki L; Marques NV; Moraes AB; Gasparetto EL; Takiya CM; Castro M; Gadelha MR
    PLoS One; 2013; 8(10):e77406. PubMed ID: 24098585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen Receptor α, a Sex-Dependent Predictor of Aggressiveness in Nonfunctioning Pituitary Adenomas: SSTR and Sex Hormone Receptor Distribution in NFPA.
    Øystese KA; Casar-Borota O; Normann KR; Zucknick M; Berg JP; Bollerslev J
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3581-3590. PubMed ID: 28911153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
    Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
    Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness.
    Qian ZR; Sano T; Asa SL; Yamada S; Horiguchi H; Tashiro T; Li CC; Hirokawa M; Kovacs K; Ezzat S
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1904-11. PubMed ID: 15070963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast Growth Factor Receptor-4 Expression in Pituitary Adenomas is Associated with Aggressive Tumor Features.
    Durcan E; Keskin FE; Ozkaya HM; Sirolu S; Sahin S; Korkmaz OP; Gazioglu N; Tanriover N; Comunoglu N; Oz B; Kizilkilic O; Kadioglu P
    Exp Clin Endocrinol Diabetes; 2022 Feb; 130(2):125-133. PubMed ID: 34255320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTTG and Ki-67 expression in pituitary adenomas.
    Wierzbicka-Tutka I; Sokołowski G; Bałdys-Waligórska A; Adamek D; Radwańska E; Gołkowski F
    Przegl Lek; 2016; 73(2):53-8. PubMed ID: 27197423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
    Taboada GF; Luque RM; Bastos W; Guimarães RF; Marcondes JB; Chimelli LM; Fontes R; Mata PJ; Filho PN; Carvalho DP; Kineman RD; Gadelha MR
    Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of somatostatin receptors, angiogenesis and proliferation markers in pituitary adenomas: an immunohistochemical study with diagnostic and therapeutic implications.
    Magagna-Poveda A; Leske H; Schmid C; Bernays R; Rushing EJ
    Swiss Med Wkly; 2013; 143():w13895. PubMed ID: 24222652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma).
    Yu B; Zhang Z; Song H; Chi Y; Shi C; Xu M
    Med Sci Monit; 2017 Apr; 23():1947-1955. PubMed ID: 28434012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine 2 and somatostatin 1-5 receptors coexpression in clinically non-functioning pituitary adenomas.
    Gabalec F; Drastikova M; Cesak T; Netuka D; Masopust V; Machac J; Marek J; Cap J; Beranek M
    Physiol Res; 2015; 64(3):369-77. PubMed ID: 25536318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prothymosin-alpha and Ki-67 expression in pituitary adenomas.
    Wierzbicka-Tutka I; Sokołowski G; Bałdys-Waligórska A; Adamek D; Radwańska E; Gołkowski F
    Postepy Hig Med Dosw (Online); 2016 Nov; 70(0):1117-1123. PubMed ID: 27892895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
    Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
    Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas.
    Yao X; Gao H; Li C; Wu L; Bai J; Wang J; Li Y; Zhang Y
    J Neurooncol; 2017 Apr; 132(2):199-206. PubMed ID: 28255749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience.
    Rishi A; Sharma MC; Sarkar C; Jain D; Singh M; Mahapatra AK; Mehta VS; Das TK
    Neurol India; 2010; 58(3):418-23. PubMed ID: 20644271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
    Padova H; Rubinfeld H; Hadani M; Cohen ZR; Nass D; Taylor JE; Culler MD; Shimon I
    Mol Cell Endocrinol; 2008 May; 286(1-2):214-8. PubMed ID: 18276067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary.
    Lee M; Lupp A; Mendoza N; Martin N; Beschorner R; Honegger J; Schlegel J; Shively T; Pulz E; Schulz S; Roncaroli F; Pellegata NS
    Endocr Relat Cancer; 2015 Feb; 22(1):111-9. PubMed ID: 25515731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
    Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
    Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin receptor subtype gene expression in pituitary adenomas.
    Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.
    Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR
    Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.